• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis Presenting New Data on NEATstik and New High Sensitivity Neutrophil Elastase Immunoassay at ATS 2018
Share
Conferences, NEATstik®, ProteaseTag®

ProAxsis Presenting New Data on NEATstik and New High Sensitivity Neutrophil Elastase Immunoassay at ATS 2018

May 2, 2018
-
Posted by David Ribeiro

ProAxsis confirms that new data on its ProteaseTag® technology will be presented at the American Thoracic Society Conference, which takes place between May 19th-24th in San Diego.

The University of Oxford team will be presenting data on NEATstik®, a novel point-of-care test for monitoring active neutrophil elastase in chronic diseases such as COPD, to the US respiratory community for the first time. NEATstik® gives a qualitative result from sputum in 10 minutes with minimal processing. The authors assessed 39 sputum samples and concluded that NEATstik® has the potential to identify those patients with elevated active NE concentrations which could be related to bacterial infection in patients with airways disease.

In addition, the company will be presenting data for the first time on the new, high sensitivity version of its immunoassay for measuring active neutrophil elastase. This immunoassay was developed in recognition of the fact that many researchers are seeking to measure biomarkers in respiratory fluids other than sputum, where the activity levels may be significantly lower. The assay development was co-funded by the UK’s innovation agency, Innovate UK.

Details of these two presentations can be found below:

EVALUATING THE SENSITIVITY AND SPECIFICITY OF NEATSTIK® TECHNOLOGY COMPARED TO AN ACTIVITY-BASED IMMUNOASSAY IN SPUTUM SAMPLES.

Presented by Professor Mona Bafhadhel, University of Oxford

 

AUGMENTATION OF PROTEASETAG® ACTIVE NEUTROPHIL ELASTASE IMMUNOASSAY SENSITIVITY

Presented by Dr Darragh McCafferty, ProAxsis Limited

 

Dr David Ribeiro, CEO of ProAxsis, said: “NEATstik® was registered with a European CE Mark in late 2017, and we’re delighted that the Oxford team will now be introducing initial data on the product to a US audience for the first time. We’re very grateful to Innovate UK for supporting the development of a new version of our Active Neutrophil Elastase Immunoassay, and look forward to making this product commercially available in the near future.”

 

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com

May 2, 2018

Related News

Other posts that you should not miss.
News, ProteaseTag®

ProAxsis CEO to present update at Bio-Europe Spring

March 6, 2017
-
Posted by Webmaster

Dr David Ribeiro, CEO of ProAxsis, will be attending the Bio-Europe Spring meeting, taking place in Barcelona on …

Read More
March 6, 2017
Posted by Webmaster
News, ProteaseTag®

ProAxsis abstracts at 2017 American Thoracic Society Conference

May 5, 2017
-
Posted by Webmaster

ProAxsis will be presenting further data on its ProteaseTag® technology, at the American Thoracic Society Conference, which takes …

Read More
May 5, 2017
Posted by Webmaster
Announcements, NEATstik®, News

New data demonstrates high potential of NEATstik® as a rapid point-of-care monitoring tool for lung diseases

June 3, 2019
-
Posted by Webmaster

Positive early data from the BRIDGE1 study, a three-year 1000+ patient study in bronchiectasis funded by the …

Read More
June 3, 2019
Posted by Webmaster
← PREVIOUS POST
ProAxsis receives further backing from Invest Northern Ireland under EU investment
NEXT POST →
New opportunity for Early Stage Researcher at Queen’s University Belfast
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis Presenting New Data on NEATstik and New High Sensitivity Neutrophil Elastase Immunoassay at ATS 2018 - ProAxsis